Ischemia Care chosen for exclusive medical device accelerator program
August 7, 2019
Ischemia Care (ISC), the parent company of Ischemic Stroke Lab, is honored to be chosen from a pool of almost 800 applicants by MedTech Innovator as one of 50 leading medtech startups transforming the healthcare industry. The ISC team is honored and excited to participate in the 2019 Accelerator & Showcase program, learning from the invaluable mentorship of key industry leaders.
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Their mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. Their track record of selecting and developing high potential companies is impressive, in only the 7th year of operation they have awarded $1.9M in prize money to 185 alumni companies, who have continued on to raise an additional $957M in follow on funding.
“Medtech Innovator stands alone for their commitment to helping patients by providing resources, advice, networking, and exposure to fuel the next generation of disruptive medtech companies,” noted CEO Jeff June. “We are honored to be recognized and included with such an impressive group of companies that have seen this program as an inflection point in their path to reaching patients and positively impacting care,”
Ischemic Stroke Lab is launching the ISCDx test for stroke etiology in 2019. This is the first blood test for cause of stroke, relying on a proprietary analysis of gene expression developed and validated through the BASE Clinical trial. The company believes this new information will empower clinicians to identify cause of stroke more often and provide guideline driven medical management proven to reduce recurrence. Each year in the United States 250,000 patients receive a diagnosis of cryptogenic stroke (unknown cause) and 185,000 patients suffer a secondary stroke that is often much more devastating.